Pressrelease - No. 6/2017
New analysis shows Soliqua® 100/33 lowered HbA1c by more than 2% in patients with screening levels
greater than 9%
- All subgroups treated with Soliqua® 100/33 achieved a mean HbA1c of
less than 7% after 30 weeks
Copenhagen, June 10, 2017 - Zealand Pharma's ("Zealand") partner Sanofi announced today that
Soliqua® 100/33 (insulin glargine and lixisenatide injection) 100 units/ml and 33 mcg/ml lowered mean blood sugar
levels (HbA1c) by 1.09-2.41% after 30 weeks in adults with type 2 diabetes previously treated with 15-40 units of basal
insulin daily.
The abstract is entitled "iGlarLixi Reduces A1c to a Greater Extent Than Basal Insulin Therapy Regardless of
A1c Levels at Screening" (Niemoeller E et al. Poster presentation 1079-P, American Diabetes Association (ADA) 77th
Scientific Sessions, San Diego, CA, U.S., June 10). This new post-hoc analysis of data from the LixiLan-L Phase 3 study, which
grouped participants according to HbA1c level at screening, also showed that all subgroups achieved a mean
HbA1c of less than 7% during the study period.1
Zealand's first invented medicine, lixisenatide, a once-daily prandial GLP-1 receptor agonist for the treatment of type 2
diabetes, is licensed to Sanofi. Soliqua® 100/33 is an injectable prescription medicine that contains two diabetes
medicines, insulin glargine and lixisenatide, that may improve blood sugar (glucose) control in adults with type 2 diabetes when
used in conjunction with diet and exercise in people who are not controlled with long-acting (basal) insulin (less than 60 units
daily) or lixisenatide. Soliqua® 100/33, which is intended to be used in conjunction with diet and exercise, is marketed
as Suliqua® in the EU.
For further information, please contact:
Britt Meelby Jensen, CEO and President
Tel.: +45 51 67 61 28, e-mail: bmj@zealandpharma.com
Mats Blom, Executive Vice President, Chief Financial Officer
Tel.: +45 31 53 79 73, e-mail: mabl@zealandpharma.com
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, design and
development of innovative peptide-based medicines. Zealand has a portfolio of medicines and product candidates under license
collaborations with Sanofi, Boehringer Ingelheim and Helsinn, and a pipeline of internal product candidates focusing on specialty
gastrointestinal and metabolic diseases.
Zealand's first invented medicine, lixisenatide, a once-daily prandial GLP-1 receptor agonist for the treatment of type 2
diabetes, is licensed to Sanofi. Lixisenatide is marketed as Adlyxin® in the U.S. and as Lyxumia® in the rest
of the world. Lixisenatide has been developed in a combination with basal insulin glargine (Lantus®) and is marketed as
Soliqua® 100/33 in the U.S. and has been approved as Suliqua® in Europe and launched in the Netherlands.
Zealand's clinical pipeline includes: dasiglucagon* (ZP4207, single-dose rescue treatment) for acute, severe hypoglycemia (Phase
2); glepaglutide* (ZP1848) for short bowel syndrome (Phase 2); dasiglucagon* (ZP4207, multiple-dose version) intended for use in a
dual-hormone artificial pancreas system to reduce the risk of hypoglycemia and better diabetes management (Phase 2) and other
earlier-stage clinical and preclinical peptide therapeutics.
Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the Company's business and activities, please
visit www.zealandpharma.com or follow Zealand on Twitter @ZealandPharma.
* Dasiglucagon and glepaglutide are proposed International Nonproprietary Names (pINN).
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/02267735-d0eb-44a6-a4b0-3d0a98e3a455
